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INTRODUCTION
Invasive breast cancer can be transferred to the lymph nodes, 
such that evaluation of axillary lymph node metastasis using 
clinical examination, sentinel lymph node biopsy (SLNB), or ax-
illary lymph node dissection (ALND) is necessary:1 SLNB can 
be used to identify axillary lymph node metastasis in patients 
with early breast cancer.2,3 Ductal carcinoma in situ (DCIS) is a 
localized tumor within the ducts without invasion of the base-
ment membrane. By definition, pure DCIS has no potential to 
spread tumor cells to the axillary lymph nodes. Therefore, ac-
cording to international guidelines, routine use of SLNB and 
ALND is not recommended for patients with DCIS.1,3 Howev-
er, in actual practice, controversy remains as to whether SLNB 
should be performed in DCIS diagnosed via preoperative bi-
opsy.4-6 A major concern for surgeons is that additional axillary 
surgery for the evaluation of metastasis to the axillary lymph 
nodes may be necessary in cases with preoperative DCIS when 
invasive foci are identified in the permanent pathology. When 
DCIS is preoperatively diagnosed with a core needle biopsy (CNB), 
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an invasive component can be under-estimated because of sam-
pling limitations. In a meta-analysis of 52 studies, approximate-
ly 26% of cases of DCIS diagnosed using CNB were upstaged 
to invasive cancer.7 Thus, a previous study suggested routine use 
of SLNB in patients with DCIS.8 However, SLNB is not a risk-
free procedure, and although it has lower morbidity rates than 
ALND, a risk of complications remains (e.g., seroma, lymphede-
ma of the arm, pain, and sensory deterioration in the axillary re-
gion). Therefore, shared decision-making in terms of perform-
ing or omitting SLNB at the time of surgery for patients with 
preoperative DCIS is crucial.
To enhance shared decision-making, predicting upstaging 
of preoperative DCIS can be helpful for patients and surgeons. 
Several studies have been conducted to establish a nomogram 
for predicting the possibility of preoperative DCIS upstaging to 
invasive ductal carcinoma after surgery.9-14 However, previous 
nomograms have had several limitations, including the lack of 
external validation, lack of clinical utility based on sophisticat-
ed variables, and lack of popularity or accessibility. Therefore, we 
conducted this study to validate a previous nomogram using an 
independent external cohort, to reanalyze factors associated with 
DCIS underestimation, and to establish an updated nomogram.
MATERIALS AND METHODS
Patient cohort
We used the Breast Cancer Registry database of Severance Hos-
pital, Yonsei University Health System, to perform a retrospec-
tive analysis. The computerized medical database was construct-
ed in MS Access (Microsoft, Seattle, WA, USA) and contained 
information on patient clinical characteristics, pathologic data 
of preoperative or postoperative evaluations, treatment meth-
ods, recurrence data, preoperative evaluation findings, includ-
ing those of physical examination, mammography, and ultraso-
nography, and follow-up data.
From 2009 to 2012, 538 patients were preoperatively diagnosed 
with DCIS and underwent definitive surgery. Patients were ex-
cluded from the analysis if they had no available data on the type 
of treatment or molecular characteristics, such as hormone re-
ceptors and human epidermal growth factor receptor 2 (HER2) 
status (Fig. 1).
Patients underwent breast-conserving surgery or mastecto-
my at their surgeons’ discretion based on the size, location, and 
multiplicity of the tumor, as well as according to the patient’s 
preference. Along with breast surgery, axillary lymph node eval-
uation was performed via SLNB and/or standard level I/II ALND. 
After surgery, patients who underwent breast-conserving sur-
gery received adjuvant radiotherapy with a median boost dose 
of 10 Gy that covered the whole breast with or without the re-
gional nodal area. Adjuvant endocrine therapy was adminis-
tered, if indicated.
Patient characteristics, including age, preoperative biopsy 
methods, clinical findings, pathologic findings, and treatment 
methods, were reviewed. We enrolled 115 additional patients 
who underwent surgery from 2013 to 2015 for independent ex-
ternal validation of the nomogram. This study was reviewed and 
approved by the Institutional Review Board of Severance Hos-
pital, Yonsei University Health System (IRB No. 4-2018-1027).
Preoperative biopsy methods
Patients were categorized according to preoperative biopsy into 
CNB and vacuum-assisted biopsy (VAB) groups. CNB was per-
formed with a 14-gauge semi-automated core needle under ul-
trasound guidance. In general, four to six core pieces were ob-
tained by radiologists specializing in breast imaging during CNB. 
VAB was performed with an 8- or 11-gauge vacuum-assisted large 
CNB system under stereotactic or ultrasound guidance. 
Clinical examination and radiology
Preoperative imaging evaluation including mammography and 
ultrasonography was performed by experienced radiologists, 
and the initial report of the preoperative imaging studies was an-
alyzed in conjunction with the final pathology to review the cor-
relation between imaging studies and the final pathology. The 
final assessment of the imaging studies was recorded with the 
Breast Image and Reporting Data System developed by the Amer-
ican College of Radiology (https://www.acr.org/-/media/ACR/
Files/RADS/BI-RADS/BIRADS-Reference-Card.pdf). The size 
of lesions on ultrasonography was reviewed using medical re-
cords. A preoperative physical examination was performed by 
experienced surgeons, and a palpable mass was described with 
or without information on the location or size of the lesions in 
the medical database. 
Histopathology
Final pathology records were reviewed to analyze histopatho-
logical variables, including suspicious invasive foci in preoper-
ative pathologic findings, presence of comedo necrosis, DCIS 
nuclear grade, Van Nuys Prognostic Index, hormone receptor 
status, amplification of HER2/neu, Ki-67 proliferative index lev-
Preoperative diagnosed DCIS and underwent 
definitive surgery between 2009 to 2012; 
538 cases
Postoperative diagnosed DCIS;
345 cases
Postoperative diagnosed 
invasive cancer; 
99 cases
Exclude unavailable data of treatment 
or molecular character; 
94 cases
Fig. 1. Patient cohort. DCIS, ductal carcinoma in situ.
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el, and number of metastatic axillary lymph nodes. Comedo ne-
crosis was considered to be either absent or present. Nuclear 
grade was determined according to the College of American Pa-
thologists guidelines. Estrogen receptor (ER), progesterone 
receptor (PR), and HER2/neu expression in primary breast can-
cer was evaluated based on formalin-fixed, paraffin-embedded 
whole sections of surgically resected breast cancer specimens 
using immunohistochemistry (IHC). The cut-off value for ER 
and PR positivity was over 1% staining in IHC. A staining level 
of 3+ on IHC was defined as positive for HER2/neu overexpres-
sion and/or when amplification was evident in a fluorescence 
in situ hybridization assay. 
Statistical analysis
Using data from 444 patients with preoperative DCIS, we ana-
lyzed categorical variables using the chi-square test or Fisher’s 
exact test. Continuous variables were analyzed using Student’s 
t-test. The significant factors estimated by the aforementioned 
analyses were confirmed using univariate logistic regression. To 
identify factors independently associated with invasion, binary 
logistic regression analysis adjusted for significant factors in the 
univariate analysis was performed. To reduce the risk of mul-
ticollinearity, some of the closely correlated variables were ex-
cluded from the multivariate analysis. The significant factors 
from the multivariate analysis were used to construct the up-
dated nomogram. 
Nomogram performance was quantified with respect to dis-
crimination and calibration using the C-index and Hosmer—
Lemeshow goodness of fit test in internal validation. The nomo-
gram was externally validated using independent data sets. 
Discrimination was quantified using the means of the area un-
der the receiver operating characteristic (ROC) curve. The cal-
ibration of the model was assessed graphically, and the area 
under the curve (AUC) was estimated. p values <0.05 were con-
sidered significant; all tests were two-sided. Statistical analyses 
were conducted using commercially available statistical soft-
ware (SPSS Statistics 24; IBM Corp., Armonk, NY, USA).
RESULTS
Clinicopathologic characteristics
Patient and tumor characteristics are shown in Table 1. A total 
of 345 patients were found to have pure DCIS, whereas 99 pa-
tients had invasive cancer. Approximately one-fifth (22.3%) of 
preoperative DCIS cases was upstaged to invasive cancer in the 
final pathology. Axillary evaluation was performed in almost 
all patients (99.1%). Axillary lymph node metastasis was found 
in 2.0% of patients in the DCIS group and in 13.1% of patients 
in the invasive cancer group. Age at diagnosis (p=0.887), pro-
portion of palpability of the lesion in physical examination 
(p=0.501), presence of calcification on imaging (sono calcifica-
tion p=0.659, mammo calcification p=0.126), and ER status 
(p=0.151) did not differ significantly between the groups.
Factors associated with prediction of invasive cancer
Table 1 shows the predictive factors associated with invasiveness 
in 444 patients with preoperative DCIS. Operation type (p<0.001), 
presence of comedo necrosis (p<0.001), existence of mass find-
ing on sonography (p<0.001) or mammography (p=0.001), pre-
Table 1. Clinicopathologic Characteristics of the Training Data Set (n=444)
DCIS (n=345) Invasive cancer (n=99)
p value
n % n %
Age at diagnosis 0.887
Same or less than 50 184 53.3 52 52.5
Older than 50 161 46.7 47 47.5
BCS probability <0.001
Yes (BCS) 177 51.3 30 30.3
No (Mastectomy) 168 48.7 69 69.7
Estrogen receptor 0.151
Negative 106 30.7 38 38.4
Positive 239 69.3 61 61.6
Progesterone receptor 0.503
Negative 182 52.8 56 56.6
Positive 163 47.2 43 43.4
HER2/neu 0.028
Negative 112 32.5 44 44.4
Overexpression 233 67.5 55 55.6
KI67 0.104
Same or less than 14 336 97.4 99 100.0
More than 14 9 2.6 0 0.0
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Table 1. Clinicopathologic Characteristics of the Training Data Set (n=444) (Continued)
DCIS (n=345) Invasive cancer (n=99)
p value
n % n %
Grade 0.838
Low/intermediate 213 61.7 60 60.6
High 132 38.3 39 39.4
Van Nuys group 0.092
Group 1 9 29.0 2 22.2
Group 2 6 19.4 5 55.6
Group 3 16 51.6 2 22.2
Comedo necrosis <0.001
Non-comedo 91 26.4 46 46.5
Comedo 254 73.6 53 53.5
USG mass <0.001
Absent 108 31.3 13 13.1
Present 237 68.7 86 86.9
USG calcification 0.659
Absent 183 53.0 55 55.6
Present 162 47.0 44 44.4
USG category 0.092
Category 1–3 11 3.2 1 1.0
Category 4–5 328 95.1 93 93.9
Category 6 6 1.7 5 5.1
MMG mass 0.001
Absent 294 85.2 70 70.7
Present 51 14.8 29 29.3
MMG calcification 0.126
Absent 85 24.6 32 32.3
Present 260 75.4 67 67.7
MMG category 0.339
Category 1–3 21 6.3 3 3.1
Category 4–5 298 90.0 92 94.8
Category 6 12 3.6 2 2.1
Biopsy method <0.001
FNAB/core needle biopsy 220 63.8 83 83.8
VAB/stereotactic biopsy 125 36.2 16 16.2
Suspicious invasion in preoperative biopsy <0.001
Absent 333 96.5 85 85.9
Present 12 3.5 14 14.1
Palpability 0.501
Non-palpable 86 24.9 28 28.3
Palpable 259 75.1 71 71.7
Axillary evaluation <0.001
Not done 3 0.9 1 1.0
SLNB 78 22.6 17 17.2
ALND 264 76.5 81 81.8
Axillary lymph node metastasis <0.001
Absent 338 98.0 86 86.9
Present 7 2.0 13 13.1
DCIS, ductal carcinoma in situ; BCS, breast-conserving surgery; HER2/neu, human epidermal growth factor receptor 2; USG, breast sonography; MMG, mam-
mography; FNAB, fine needle aspiration biopsy; VAB, vacuum-assisted biopsy; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection.
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operative biopsy method (p<0.001), and suspicious microinva-
sion in preoperative biopsy (p<0.001) were significantly related 
to upstaging to invasive cancer in the postoperative pathology. 
Univariate logistic regression analysis of the 444 patients with-
out missing data revealed seven significant variables: operation 
type [odds ratio (OR)=2.42, 95% confidence interval (CI)=1.50–
3.91, p<0.001], HER2 overexpression (OR=0.6, 95% CI=0.38–0.95, 
p=0.028), presence of comedo necrosis in the tumor (OR=0.41, 
95% CI=0.26–0.66, p<0.001), sonographic mass (OR=3.01, 95% 
CI=1.61–5.64, p<0.001), mammographic mass (OR=2.39, 95% 
CI=1.41–4.04, p=0.001), VAB/stereotactic biopsy as the preop-
erative biopsy method (OR=0.34, 95% CI=0.19–0.61, p<0.001), 
and presence of suspicious microinvasive foci in preoperative 
biopsy (OR=4.58, 95% CI=2.04–10.24, p<0.001) (Table 2). 
In multivariate analysis, operation type (OR=3.46, 95% CI=2.02–
5.91, p<0.001), sonographic mass (OR=2.75, 95% CI=1.40–5.38, 
p=0.003), mammographic mass (OR=2.23, 95% CI=1.24–4.01, 
p=0.007), and suspicious microinvasion in preoperative biop-
sy (OR=3.96, 95% CI=1.59–9.84, p=0.003) were risk factors for 
upstaging to invasive cancer after surgery. In cases of DCIS with 
HER2 overexpression (OR=0.55, 95% CI=0.33–0.93, p=0.024) and 
comedo necrosis (OR=0.4, 95% CI=0.24–0.67, p<0.001), a diag-
nosis of pure DCIS after surgery was highly likely (Table 3).
Nomogram establishment and validation 
The updated nomogram is illustrated in Fig. 2. The detailed es-
tablishment process of the nomogram was described in a pre-
vious study.10 The valuation of the updated model with the six 
significant variables showed moderate discrimination (C-in-
dex=0.75) and was appropriate in a calibration test (p=0.452). Ex-
ternal validation with an independent data set of 115 patients 
showed moderate to strong discrimination, with a C-index of 
0.66, and good fit, with a calibration test result of 0.92. The ROC 
curve is illustrated in Fig. 3, and the AUC was 0.621 (95% CI= 
0.496–0.746). 
DISCUSSION
It is important to predict the probability of invasive cancer be-
fore surgery, since it has a large impact on the range of surgery 
and the complications that patients should endure. This pro-
cess can facilitate shared decision making between surgeons 
and patients. Therefore, more accurate and accessible methods 
are needed to predict invasiveness in preoperative diagnosed 
DCIS. In 2013, we published a nomogram that predicted the in-
vasiveness of breast cancer diagnosed as pre-operative DCIS, 
and several other studies utilized it in the past few years.10,12-14 
However, since the previous model had some limitations, it had 
to be updated using recent data. Therefore, we conducted this 
study to update the new nomogram. This updated nomogram 
was found to be more accurate in predicting invasive potential 
than the previous model and to be potentially more helpful for 
many surgeons and patients.
A previous study established a nomogram to predict the like-
lihood of postoperative invasive ductal carcinoma in DCIS at 
Table 2. Univariate Logistic Regression Analysis of the Training Data Set
OR 95% CI p value
Age at diagnosis 0.887
Same or less than 50 Ref.
Older than 50 1.03 0.66–1.62
BCS probability <0.001
Yes (BCS) Ref.
No (Mastectomy) 2.42 1.50–3.91
Estrogen receptor 0.152
Negative Ref.
Positive 0.71 0.45–1.13
Progesterone receptor 0.502
Negative Ref.
Positive 0.86 0.55–1.35
HER2/neu 0.028
Negative Ref.
Overexpression 0.6 0.38–0.95
Grade 0.837
Low/intermediate Ref.
High 1.05 0.66–1.66
Comedo necrosis <0.001
Non-comedo Ref.
Comedo 0.41 0.26–0.66
USG mass 0.001
Absent Ref.
Present 3.01 1.61–5.64
USG calcification 0.658
Absent Ref.
Present 0.9 0.58–1.42
MMG mass 0.001
Absent Ref.
Present 2.39 1.41–4.04
MMG calcification 0.126
Absent Ref.
Present 0.68 0.42–1.11
Biopsy method <0.001
FNAB/core needle biopsy Ref.
VAB/stereotactic biopsy 0.34 0.19–0.61
Suspicious invasion in preoperative biopsy <0.001
Absent Ref.
Present 4.58 2.04–10.24
Palpability 0.500
Non-palpable Ref.
Palpable 0.84 0.51–1.39
OR, odds ratio; CI, confidence interval; BCS, breast-conserving surgery; 
HER2/neu, human epidermal growth factor receptor 2; USG, breast sonogra-
phy; MMG, mammography; FNAB, fine needle aspiration biopsy; VAB, vacu-
um-assisted biopsy.
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diagnosis.10,15 The application of the previous nomogram was 
checked by Jakub, et al.13 in their study, which showed poor cal-
ibration (p=0.002). We also performed an external validation of 
the previous nomogram using independent datasets, and it did 
not show high performance. The AUC of the ROC curve for com-
parison with the previous version of the nomogram was 0.48 
(Supplementary Fig. 1, only online). The reason for this was that 
DCIS underestimation was approximately 40% among the pa-
tients assessed with the previous nomogram, which was 22% in 
the validation group.10,15 This was due to the difference in patient 
populations between the previous data and the validation data. 
The previous study was conducted using data from 2000 to 2008, 
and the independent cohort used data from patients who were 
diagnosed from 2009 to 2012. The number of actual DCIS pa-
tients increased recently because the proportion of patients who 
were diagnosed via breast screening increased, which led to an 
increased number of patients diagnosed with DCIS. In addition, 
No (mastectomy)
Present
Present
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Yes (BCS)
0
0
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
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Negative
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Points
BCS probability
HER2/neu
Comedo necrosis
Sonographic mass
MMG mass
Suspicious invasion
Total points
Probability
Fig. 2. An updated nomogram. BCS, breast-conserving surgery; HER2/neu, human epidermal growth factor receptor 2; MMG, mammographic.
Fig. 3. Receiver operating characteristic curve for external validation with 
the independent data set (n=115). AUC, area under the curve.
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Table 3. Multivariate Logistic Regression Analysis of Factors associated 
with Upstaging of Preoperative Ductal Carcinoma In Situ in the Training 
Data Set
OR 95% CI p value
BCS probability <0.001
Yes (BCS) Ref.
No (Mastectomy) 3.46 2.02–5.91
HER2/neu 0.024
Negative Ref.
Overexpression 0.55 0.33–0.93
Comedo necrosis <0.001
Non-comedo Ref.
Comedo 0.4 0.24–0.67
USG mass 0.003
Absent Ref.
Present 2.75 1.40–5.38
MMG mass 0.007
Absent Ref.
Present 2.23 1.24–4.01
Suspicious invasion in preoperative biopsy 0.003
Absent Ref.
Present 3.96 1.59–9.84
OR, odds ratio; CI, confidence interval; BCS, breast-conserving surgery; 
HER2/neu, human epidermal growth factor receptor 2; USG, breast sonogra-
phy; MMG, mammography.
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diagnostic skills for pathologists may have improved over time, 
which may have influenced the accuracy of preoperative diag-
nosis. Hence, the previous nomogram may be over-fitted. Ac-
cordingly, we re-analyzed the risk factors that underestimated 
invasive cancer with DCIS in preoperative diagnosis.
Consequently, the significant predictive factors were sono-
graphic mass, mammographic mass, comedo necrosis, overex-
pression of HER2/neu, suspicious microinvasion in preopera-
tive examination, and operation type. Most of the patients who 
underwent mastectomy had breast cancer of large size or multi-
centricity. Previous studies have attempted to include the size 
of lesions as a predictor of risk in nomograms.11,13,15 Lesion size 
and multi-centricity on imaging were not used in this study be-
cause they are often difficult to measure and inaccurate because 
of the ambiguity of the extent of microcalcification on mam-
mography, non-circumscribed margin, or hypoechoic microcal-
cified lesions on ultrasound, as well as background enhance-
ment of magnetic resonance imaging. Instead of lesion size and 
multi-centricity, we inferred the impact of breast cancer size and 
multi-centricity based on the operation type. In validation us-
ing an external independent cohort, the updated nomogram 
showed moderate-to-strong discrimination of upgrading pre-
operative DCIS, and its performance was higher than that of the 
previous nomogram (AUC for external validations, 0.62 vs. 0.4). 
Our previous study identified palpability, calcification on so-
nography, sonographic mass, previous biopsy methods, and 
presence of suspicious microinvasion foci as related factors to 
predict invasive cancer in postoperative pathology.10 The palpa-
bility and existence of calcification on sonography were not sig-
nificant in the current study. This may have been due to DCIS 
being increasingly detected via screening over time.16,17
DCIS underestimation on biopsy has been reported to de-
crease as the amount of tissue acquired increases, and the DCIS 
underestimation rate in VAB is lower than that in CNB.18 The 
previous nomogram also included biopsy methods as a predic-
tor of risk.10,15 Regarding the preoperative biopsy method, VAB/
stereotactic biopsy showed lower upstaging of invasive cancer 
than CNB in univariate analysis (VAB vs. CNB: 11.3% vs. 27.4%, 
OR=0.34, 95% CI=0.19–0.61, p<0.001). However, no significance 
was found in the multivariate analysis in this study. Hence, pre-
operative biopsy method was excluded from the predictors of 
risk in the establishment of the nomogram. Nevertheless, it tend-
ed to lower the underestimation of invasive cancer (OR=0.56, 
95% CI=0.29–1.07, p=0.077). Further study is needed to evalu-
ate the role of VAB in the detection of invasiveness in preoper-
ative DCIS.
Sonographic mass and mammographic mass may be relat-
ed to each other. Therefore, we checked their relationship using 
McNemar’s test, and they showed different values and low con-
cordance (p<0.001). Hence, both factors were used as predictors 
of risk.
Some studies have reported that subtypes of DCIS, such as 
non-cribriform type, papillary type, solid type, and comedo ne-
crosis, are related to upstaging to invasive cancer.11 In this study, 
we reviewed the presence of comedo necrosis but not other sub-
types, and comedo necrosis showed significant association with 
pure DCIS after surgery (OR=0.4, 95% CI=0.24–0.67, p=0.003). 
This study has some limitations. This was a retrospective and 
single-institution study. The study was analyzed and validated 
using similar imaging and pathology interpreted in the same in-
stitution. This mostly uniform design in a single institution could 
be a definite advantage. However, pathological and image inter-
pretation methods vary according to institution, and these may 
not be reflected in our nomogram.
In conclusion, the previous version of the nomogram did not 
effectively discriminate upstaging of preoperative DCIS in an 
independent cohort. Our updated version of the nomogram pro-
vides more accurate information for predicting upstaging of 
preoperative DCIS.
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